MAO inhibitors: risks, benefits, and lore

Cleve Clin J Med. 2010 Dec;77(12):859-82. doi: 10.3949/ccjm.77a.09103.

Abstract

Monoamine oxidase (MAO) inhibitors were the first antidepressants introduced, but their use has dwindled because of their reported side effects, their food and drug interactions, and the introduction of other classes of agents. However, interest in MAO inhibitors is reviving. Here, we discuss their use, risks, and benefits in clinical medicine.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Administration, Cutaneous
  • Antidepressive Agents / adverse effects*
  • Antidepressive Agents / therapeutic use
  • Blood Pressure / drug effects*
  • Cheese
  • Depressive Disorder, Major / drug therapy
  • Feeding Behavior
  • Food-Drug Interactions
  • Humans
  • Hypertension / chemically induced*
  • Hypertension / prevention & control
  • Monoamine Oxidase Inhibitors / adverse effects*
  • Monoamine Oxidase Inhibitors / therapeutic use
  • Myocardium
  • Risk Factors
  • Selegiline / adverse effects
  • Selegiline / pharmacokinetics
  • Selegiline / therapeutic use*
  • Tyramine

Substances

  • Antidepressive Agents
  • Monoamine Oxidase Inhibitors
  • Selegiline
  • Tyramine